JP2011501176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501176A5 JP2011501176A5 JP2010530497A JP2010530497A JP2011501176A5 JP 2011501176 A5 JP2011501176 A5 JP 2011501176A5 JP 2010530497 A JP2010530497 A JP 2010530497A JP 2010530497 A JP2010530497 A JP 2010530497A JP 2011501176 A5 JP2011501176 A5 JP 2011501176A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- inflammatory
- symptoms
- patient
- disease progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024891 symptom Diseases 0.000 claims description 14
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 8
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 8
- 206010063837 Reperfusion injury Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000000451 tissue damage Effects 0.000 claims description 5
- 231100000827 tissue damage Toxicity 0.000 claims description 5
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 208000034486 Multi-organ failure Diseases 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20070795 | 2007-10-24 | ||
| FI20070795A FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| PCT/FI2008/050576 WO2009053523A1 (en) | 2007-10-24 | 2008-10-15 | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012098081A Division JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501176A JP2011501176A (ja) | 2011-01-06 |
| JP2011501176A5 true JP2011501176A5 (enExample) | 2012-04-19 |
| JP4982610B2 JP4982610B2 (ja) | 2012-07-25 |
Family
ID=38656804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530497A Expired - Fee Related JP4982610B2 (ja) | 2007-10-24 | 2008-10-15 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
| JP2012098081A Expired - Fee Related JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012098081A Expired - Fee Related JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100209942A1 (enExample) |
| EP (2) | EP2201376B1 (enExample) |
| JP (2) | JP4982610B2 (enExample) |
| KR (2) | KR20160029869A (enExample) |
| CA (1) | CA2702635A1 (enExample) |
| CY (2) | CY1113403T1 (enExample) |
| DK (2) | DK2201376T3 (enExample) |
| ES (2) | ES2532361T3 (enExample) |
| FI (1) | FI20070795A0 (enExample) |
| HR (2) | HRP20120743T1 (enExample) |
| PL (2) | PL2201376T3 (enExample) |
| PT (2) | PT2201376E (enExample) |
| SI (2) | SI2201376T1 (enExample) |
| WO (1) | WO2009053523A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201704689XA (en) | 2008-01-18 | 2017-07-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| SG10201505723UA (en) | 2010-07-23 | 2015-09-29 | Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
| CA2806301A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| EA201590024A1 (ru) | 2012-06-15 | 2015-05-29 | Гарри Стилли | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток |
| CN104603289A (zh) | 2012-06-15 | 2015-05-06 | 哈里·斯泰利 | 检测疾病或病状的方法 |
| PL2956772T3 (pl) * | 2013-02-14 | 2018-12-31 | Faron Pharmaceuticals Oy | Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| EP4428251A3 (en) | 2014-09-11 | 2024-12-18 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| ES2826566T3 (es) | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| GB201706747D0 (en) | 2017-04-27 | 2017-06-14 | Queen Mary | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients |
| GB201715115D0 (en) | 2017-09-19 | 2017-11-01 | Univ London Queen Mary | Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997007236A1 (en) * | 1995-08-18 | 1997-02-27 | Landry Donald W | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| WO1997013875A1 (en) | 1995-10-13 | 1997-04-17 | Imperial College Of Science, Technology & Medicine | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
| HUP0002003A3 (en) | 2000-05-24 | 2003-01-28 | Pronuk Biotechnologia Kft | Process and reagent-kit for determining of 5'-nucleotidase activity |
| CA2439961A1 (en) * | 2001-03-27 | 2002-10-03 | Zymogenetics, Inc. | Human cytokine receptor |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| US7534423B2 (en) * | 2003-03-28 | 2009-05-19 | Faron Pharmaceuticals Oy | Method for inducing an elevated level of adenosine in an individual |
| FI20030467A0 (fi) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Menetelmä tulehdustilojen hoitamiseen |
| CA2528152A1 (en) * | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
| WO2007025044A2 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| FI20051003A0 (fi) | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| WO2007107598A1 (en) * | 2006-03-21 | 2007-09-27 | Heinrich-Heine-Universität Düsseldorf | Phosphorylated a2a receptor agonists |
| EP3796002B1 (en) * | 2006-07-14 | 2023-11-22 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
-
2007
- 2007-10-24 FI FI20070795A patent/FI20070795A0/fi not_active Application Discontinuation
-
2008
- 2008-10-15 ES ES12002502.8T patent/ES2532361T3/es active Active
- 2008-10-15 KR KR1020167005473A patent/KR20160029869A/ko not_active Ceased
- 2008-10-15 SI SI200830723T patent/SI2201376T1/sl unknown
- 2008-10-15 PT PT08842581T patent/PT2201376E/pt unknown
- 2008-10-15 KR KR1020107006430A patent/KR20100059902A/ko not_active Ceased
- 2008-10-15 DK DK08842581.4T patent/DK2201376T3/da active
- 2008-10-15 CA CA2702635A patent/CA2702635A1/en not_active Abandoned
- 2008-10-15 HR HRP20120743AT patent/HRP20120743T1/hr unknown
- 2008-10-15 JP JP2010530497A patent/JP4982610B2/ja not_active Expired - Fee Related
- 2008-10-15 EP EP08842581A patent/EP2201376B1/en active Active
- 2008-10-15 WO PCT/FI2008/050576 patent/WO2009053523A1/en not_active Ceased
- 2008-10-15 SI SI200831377T patent/SI2503338T1/sl unknown
- 2008-10-15 PT PT12002502T patent/PT2503338E/pt unknown
- 2008-10-15 DK DK12002502T patent/DK2503338T3/en active
- 2008-10-15 ES ES08842581T patent/ES2389751T3/es active Active
- 2008-10-15 US US12/679,785 patent/US20100209942A1/en not_active Abandoned
- 2008-10-15 PL PL08842581T patent/PL2201376T3/pl unknown
- 2008-10-15 EP EP12002502.8A patent/EP2503338B1/en active Active
- 2008-10-15 PL PL12002502T patent/PL2503338T3/pl unknown
-
2012
- 2012-04-23 JP JP2012098081A patent/JP5619810B2/ja not_active Expired - Fee Related
- 2012-10-04 CY CY20121100924T patent/CY1113403T1/el unknown
-
2015
- 2015-02-16 HR HRP20150181TT patent/HRP20150181T1/hr unknown
- 2015-03-06 CY CY20151100234T patent/CY1116089T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martinez et al. | Idiopathic pulmonary fibrosis | |
| Nadeem et al. | Serum inflammatory markers in obstructive sleep apnea: a meta-analysis | |
| JP2016118568A5 (enExample) | ||
| BR112014014960A2 (pt) | métodos para o diagnóstico da doença de alzheimer | |
| HRP20120743T1 (hr) | Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja | |
| Paplińska et al. | Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients | |
| Aleem et al. | Correlation of C-reactive protein levels with severity of chronic urticaria | |
| Zeng et al. | Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis | |
| Juel et al. | Systemic and ocular long pentraxin 3 in patients with age-related macular degeneration | |
| JP2016502406A5 (enExample) | ||
| JP2018536152A5 (enExample) | ||
| Wei et al. | Predictive value of the serum matrix metalloproteinase-9 level on hepatic encephalopathy in patients with chronic liver disease | |
| Mkrtchyan et al. | Involvement of anomalous apoptosis in impairments to synaptic plasticity in post-traumatic stress disorder | |
| Parvanescu et al. | Gout-risks, comorbidities and associations | |
| Orlova et al. | Extrinsic interstitial lung disease activity markers | |
| Belal et al. | Pentraxin 3 is Increased Early in Blood of Patients with Cerebral Stroke and Predicts its Severity. | |
| Niaz | Association of serum resistin with lipids in hypertensives and coronary artery disease patients | |
| Holz et al. | Reproducibility of serum biomarkers and relationship to airway inflammation following LPS challenge in healthy volunteers | |
| Tew et al. | Serum Type 2 Chemokines In Chronic Obstructive Pulmonary Disease (COPD) Subjects In The Subpopulations And Intermediate Outcomes In COPD Study (spiromics) | |
| Cheng | Effects With Allergic Phenotypes Using Blood Eosinophilic Counts And Ige Levels In Patients With COPD | |
| Zhang et al. | D41 COPD: BIOMARKERS IN STABLE DISEASE AND EXACERBATIONS: Increased Serum Levels Of Lipocalin 1 And 2 In Patients With Stable Chronic Obstructive Pulmonary Disease | |
| Farfara et al. | Knockdown of Liver-Derived C1 Inhibitor Results in Brain Pathology in mice | |
| JP2012528591A5 (enExample) | ||
| Oguz et al. | OP-141 Comorbidities Accompanying Hospitalizations of Heart Failure | |
| Tew et al. | C35 INNATE IMMUNE MECHANISMS IN COPD: Serum Type 2 Chemokines In Chronic Obstructive Pulmonary Disease (COPD) Subjects In The Subpopulations And Intermediate Outcomes In COPD Study (spiromics) |